List of major projects of China's new drugs and technology trade in 2014

　　 2014 will be gone This year, Chinese pharmaceutical companies have handed over 25 projects in the field of new drugs and technology transactions, five more than last year, as of December 29 There are many common faces involved, such as Yiteng, Haizheng pharmaceutical, Geli, Jiangsu Hengrui pharmaceutical, Shenyang Sansheng pharmaceutical, Fosun Pharmaceutical and other well-known pharmaceutical companies, involving And the categories include cancer, cardiovascular, diabetes, respiratory diseases, etc On January 7, Kunshan ruiboquark Pharmaceutical Technology Co., Ltd completed a round of financing of 45 million yuan to accelerate the clinical development of qpi-1007 At present, the drug is carrying out phase III trials for the treatment of non arteritis anterior ischemic optic neuropathy and phase IIa trials for the treatment of glaucoma Qpi-1007 is a synthetic small nucleic acid drug (siRNA), which is used to block the expression of caspase-2, an apoptotic protein, and has the protective effect on optic nerve On January 8, Yiteng pharmaceutical and actbiotech reached an agreement to pay US $95 million for the global licensing of three new drugs, telatinib, actb1003 and actb1010 Telatinib is an inhibitor of VEGFR, which is used to treat gastric cancer It is currently in phase III clinical; actb1003 is an inhibitor of FGFR / VEGFR2, which is in phase I clinical; actb1010 is an aurora kinase inhibitor, which is in preclinical research On March 3, Shanxi Sequoia Pharmaceutical Co., Ltd purchased American cardiotherapeutics for us $5 million, and changed its name to Taxus cardiopharmaceuticals Generx and excellagen are two products: generx is a angiogenic Fgf4 gene therapy, which is used to treat myocardial microvascular dysfunction and is in phase III clinical research; excellagen is type I bovine collagen, which is used for wound care and has been approved by FDA On April 3, Zhejiang Haizheng Pharmaceutical Co., Ltd reached a cooperation agreement with catalentpharma solutions Haizheng will use Catalent's gpex technology to develop bio generic drugs, including infliximab, adamumumab and alenumab On April 15, the Dutch company mucosis reached a long-term cooperation and license agreement on vaccine management technology with Baike biology, a subsidiary of China Changchun hi tech group The company has raised $6.91 million (about 5 million euros) in a new round of financing Mucosis has granted the exclusive license of new respiratory syncytial virus vaccine (syngem) and mimopath technology in China and non exclusive license in Asia Meanwhile, it will subscribe for the equity of mucosis and make regular payment including royalties On April 23, Fosun Pharmaceutical reached an agreement with the global TB drug research and Development Alliance (TB alliance) to obtain the exclusive authorization for the development, registration, production and sales rights of the new anti TB drug pamz developed by the alliance in China, including Hong Kong, Macao and Taiwan (authorized regions) Pamz is composed of PA-824 and moxifloxacin, and pyrazinamide as the first-line treatment Fosun will sponsor phase III clinical trials of the drug On April 29, ambrx company and Zhejiang Haizheng Pharmaceutical Co., Ltd announced the development and commercialization of cooperative cancer treatment for bispecifics based on ambrx technology Haizheng pharmaceutical will have the commercial rights of the products in China, while ambrx will retain the commercial rights outside China and have the right to collect the copyright fees of the products sold in China On April 30, Yabao pharmaceutical and Innolux announced to form a strategic partnership to jointly develop ls-008, a PLK / PI3K dual inhibitor of Changzhou Innolux On July 7, Yabao Pharmaceutical Co., Ltd and Eli Lilly Pharmaceutical Co., Ltd reached an agreement to jointly develop a diabetes drug - glucokinase activator ly2608204; at present, the drug has completed phase I clinical treatment in the United States On August 8, Shenyang Sansheng pharmaceutical purchased anti-JL1 monoclonal antibody leukotuximab from dinona, South Korea Leukouximab is an anti-JL1 antibody for the treatment of acute leukemia (including acute lymphocytic leukemia and acute myeloid leukemia) The drug entered phase I clinical trial in South Korea in June, and Shenyang Sansheng pharmaceutical will pay advance payment, mileage and sales commission The additional terms of the license have not been disclosed On August 12, zaiding pharmaceutical and Sanofi signed a global license agreement on two new compounds, namely, potential therapeutic drugs for chronic respiratory diseases (including chronic obstructive pulmonary disease), asthma and idiopathic pulmonary fibrosis, which were discovered by Sanofi At present, both drugs are in preclinical stage Other terms of the license agreement have not been disclosed On August 21, green leaf Pharmaceutical Group will pay 20 million US dollars to Korea US Pharmaceutical Industry Co., Ltd (Korea US) to reach an agreement to jointly develop a pan her inhibitor poziotinib in clinical research stage for cancer treatment Poziotinib has the potential to treat a variety of cancers by blocking EGFR family receptors The drug has achieved clinical stage II in South Korea and is used to treat non-small cell lung cancer, breast cancer, etc On September 9, Shenzhen Beike biology purchased the right of phase I anti-cancer drug alt-803 from altor bioscience of the United States in China Altor bioscience will receive a down payment of 4 million US dollars, mileage gold of 200 million US dollars and double-digit sales commission Alt-803 was modified and recombined on the basis of IL-15 It had significant improvement in efficacy intensity and pharmacokinetics It has carried out four phase I and phase I / II combined clinical trials in the United States, and initially showed good clinical efficacy and tolerance in tumor immunotherapy On September 18, CASI Pharmaceutical (yingchuangyuanda) announced that it had signed a license agreement, and was granted the patent rights of two listed anti-tumor drugs of spectrum pharmaceutical in Greater China, including the listed drug tiemomumab, marqibo (vincristine sulfate liposome) and mefalen, a new anti-tumor drug for phase III clinical use R & D and commercialization in Greater China including Taiwan, Hong Kong and Macao Spectrum acquired 20% stake (about $10 million) and a $1.5 million promissory note September 25: Lizhu mAb biopharmaceutical Co., Ltd signed a strategic agreement with Epirus biopharmaceutical Co., Ltd of the United States to enter the Chinese market hand in hand The two companies will cooperate in R & D, production and commercialization to develop five blockbuster monoclonal antibody generic drugs Including infliximab, adamumumab and bevacizumab On October 29, Beida Pharmaceutical Co., Ltd announced to invest 20 million US dollars in xccovery company of the United States, and obtained the development right of ALK inhibitor x-396 project in China It is understood that xccovery has disclosed the phase I clinical data of the drug at the 2014 chest cancer multidisciplinary seminar On November 3, water signed a license agreement with scynexis to obtain the global rights of anti HCV drug scy-635 At present, scy-635 has completed phase II clinical trials On November 10, Geli biology signed a license agreement with Presidio to obtain the Greater China rights of ppi-668 Ppi-668, an NS5A inhibitor, is currently used in phase II clinical trials as a treatment for hepatitis C Goliath tried to use ppi-668 and danoprevir, an NS3 / 4A protease inhibitor On November 18, Shenyang Sansheng Pharmaceutical Co., Ltd signed a license agreement with pharmabine to obtain the rights of tanibirumab, an all human anti VEGFR2 monoclonal antibody The drug recruited 26 patients with advanced or metastatic cancer in South Korea to complete its phase I clinical trial The phase II study of glioblastoma is under preparation On November 21, MRC technology, a British medical research charity, and Yabao Pharmaceutical Group announced on November 21 that they had signed an exclusive cooperation agreement to jointly develop and commercialize new drugs for Parkinson's disease It is reported that the target of the drug is a kinase that plays a key role in the decline of nerve function On November 25, Zhengzhou University signed a patent technology transfer agreement with Zhejiang AoXiang Pharmaceutical Co., Ltd to transfer the "BZP" developed by Professor Chang Junbiao of Zhengzhou University for the treatment of cerebrovascular diseases to Zhejiang AoXiang Pharmaceutical Co., Ltd at a price of 45 million yuan The drug is a proprietary compound obtained from butylphthalide (NBP) for the treatment of mild to moderate acute ischemic stroke On December 1, Guoyao Yixin pharmaceutical purchased the authorization of zoptarelin doxorubicin (aezs-108, AN-152) for the treatment of endometrial cancer from aeeterna zentaris with a down payment of US $1 million At present, the drug has entered phase III clinical trials On December 3, oramed pharmaceutical company obtained an investment of 5 million yuan from Guangxi Wuzhou Pharmaceutical Co., Ltd It is reported that the proceeds from oramed will be used for clinical trials of oral insulin ormd-0801 and oral exenatide (ormd-0901) On December 19, Yiteng pharmaceutical introduced venacaran from cardiome pharma At present, Yiteng has agreed to prepay US $1 million and mileage US $3 million The drug was launched in Europe in 2010 for the treatment of atrial fibrillation On December 29, Ma Yinglong Pharmaceutical Group and Beijing kangmadico Biotechnology Development Co., Ltd signed the technology development cooperation contract, jointly participated in the research and development, applied for the treatment of all kinds of discomfort symptoms caused by vaginal atrophy in postmenopausal women, a new drug, pratestosterone sodium sulfate tablets, obtained the new drug certificate and drug registration approval